AIA Group Ltd Grows Stake in Amgen Inc. $AMGN - Defense World
📈 AIA Group Ltd increased its Amgen holdings by 11.2% in Q1, adding 2,815 shares to a total position of 27,962 shares.
💰 Amgen reported Q1 revenue of $8.62 billion, beating estimates and growing 5.8% year-over-year.
📊 The company posted EPS of $5.15, exceeding analyst consensus estimates of $4.77 by $0.38.
🏦 Institutional ownership stands at 76.5%, with several hedge funds adjusting positions in Q4 and Q1.
📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold', while Freedom Capital upgraded it to 'strong-buy'.
🎯 Analysts maintain an average price target of $356.62 for the stock.
📈 Amgen provided FY 2026 EPS guidance ranging from $21.70 to $23.10.
💼 SVP Nancy A. Grygiel sold 1,237 shares in a transaction valued at approximately $400,454.
Bullish Signals
- Amgen beat quarterly earnings estimates with EPS of $5.15 versus the consensus of $4.77.
- Revenue grew 5.8% year-over-year to reach $8.62 billion, exceeding analyst expectations of $8.58 billion.
- The company achieved a high return on equity of 137.41% and a net margin of 20.96%.
- Freedom Capital upgraded its rating from 'hold' to 'strong-buy', indicating improved confidence in the stock.
- Piper Sandler reaffirmed an 'overweight' rating, signaling continued institutional support.
- Institutional investors like AIA Group Ltd increased their stakes, demonstrating sustained interest.
Risk Factors
- Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating in late June.
- SVP Nancy A. Grygiel sold 15% of her holdings, reducing her stake by 1,237 shares.
- The stock trades at a P/E ratio of 25.49 and a PEG ratio of 3.71, which may be considered high relative to growth.
Full Analysis
AIA Group Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.2% during the first quarter, purchasing an additional 2,815 shares to own a total of 27,962 shares valued at $9.838 million. This filing highlights continued institutional interest alongside other hedge funds like Anfield Capital Management and Dogwood Wealth Management, which also adjusted their stakes significantly in the fourth quarter.
Amgen reported strong quarterly financial results ending April 30th, with revenue of $8.62 billion, a 5.8% year-over-year increase that beat analyst expectations. The company posted earnings per share of $5.15, surpassing the consensus estimate of $4.77, and achieved a net margin of 20.96%. Analysts have set an average price target of $356.62, with the stock currently trading around $366.
Analyst sentiment remains mixed but generally positive regarding the company's fundamentals. Freedom Capital upgraded Amgen to a 'strong-buy' rating, while Piper Sandler maintained an 'overweight' stance. However, Wall Street Zen downgraded the stock to a 'hold'. The company maintains a market capitalization of $197.69 billion and has provided FY 2026 EPS guidance between $21.70 and $23.10.
